6 курс / Медицинская реабилитация, ЛФК, Спортивная медицина / МЕХАНИЗМЫ_ВЛИЯНИЯ_ИНДУЦИРУЕМОЙ_АЦЕТИЛХОЛИНЭСТЕРАЗОЙ_ОЛИГОМЕРИЗАЦИИ

111

173.Semenov V.E. 6–Methyluracil derivatives as bifunctional acetylcholinesterase inhibitors for the Treatment of Alzheimer's diseaseю. / V.E. Semenov, I.V. Zueva, M.A. Mukhamedyarov, S.V. Lushchekina, A.D. Kharlamova, E.O. Petukhova, A.S. Mikhailov, S.N. Podyachev, L.F. Saifina, K.A. Petrov, O.A. Minnekhanova, V.V. Zobov, E.E. Nikolsky, P. Masson, V.S. Reznik.// ChemMedChem, 2015. – Vol. 10(11). – P. 1863–1874.

174.Semenov V.E. Macrocyclic derivatives of 6-methyluracil as ligands of the peripheral anionic site of acetylcholinesterase./ V.E. Semenov, R.Kh. Giniyatullin, S.V. Lushchekina, E.D. Kots, K.A. Petrov, A.D. Nikitashina, O.A. Minnekhanova, V.V. Zobov, E.E. Nikolsky, P. Masson, V.S. Reznik.// Med. Chem. Commun., 2014.

–Vol. 5. – P. 1729–1735.

175.Shankar G.M. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory./ G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F.M. Brett, M.A Farrell, M.J. Rowan, C.A. Lemere, C.M. Regan, D.M. Walsh, B.L. Sabatini, D.J. Selkoe.//Nat Med., 2008. – Vol. 14. – P. 837–842.

176.Shaw K.T. Phenserine regulates translation of beta –amyloid precursor protein mRNA by a putative interleukin–1 responsive element, a target for drug development./ K.T. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, A. Brossi, Y.W. Ge, D.K. Lahiri, N.H. Greig.// Proc Natl Acad Sci USA, 2001. – Vol. 19. – P. 7605–7610.

177.Shoji M. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness./ M. Shoji // Front Biosci., 2002. – Vol. 7. – P. 997–1006.

178.Siemers E. Drug development in AD: point of view from the industry. E. Siemers.// J Prev Alz Dis., 2015. – Vol. 2. – P. 216–218.

179.Sigurdsson E.M. Tau–focused immunotherapy for Alzheimer’s disease and

related tauopathies./ E.M. Sigurdsson.// Curr Alzheimer Res., 2009. – Vol. 6. – P. 446–450.

180. Sipos E. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease./ E. Sipos, A. Kurunczi, A. Kasza, J.

t.me/medicina_free

112

Horvath, K. Felszeghy, S. Laroche, J.Toldi, A. Parducz, B.Penke, Z. Penke. //

Neuroscience, 2007. –. Vol. 147. – P. 28-36.

181.Smith M.A. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease./ M.A. Smith, R.K. Kutty, P.L Richey, S.D. Yan, D. Stern, G.J Chader, B. Wiggert, R.B. Petersen, G. Perry.// Am. J. Pathol., 1994. – Vol. 145(1). – P. 42–47.

182.Smith M.A. Oxidative damage in Alzheimer's./ M.A. Smith, G. Perry, P.L. Richey, L.M. Sayre, V.E. Anderson, M.F. Beal, N. Kowall.// Nature, 1996. – Vol. 382. – P. 120–121.

183.Sowade R.F. Seed-induced acceleration of amyloid-β mediated neurotoxicity in

vivo./ R.F. Sowade, T.R. Jahn.// Nat Commun., 2017. – Vol. 8(1) :512.

184.Spires T.L. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy./ T.L. Spires, M. Meyer-Luehmann, E.A. Stern, P.J. McLean, J. Skoch, P.T. Nguyen, B.J. Bacskai, B.T. Hyman.// J Neurosci., 2005. – Vol. 25. – P. 7278–7287.

185.Stöhr J. Purified and synthetic Alzheimer's amyloid beta (Aβ) prions./ J. Stöhr, J.

Watts, Z. Mensinger, A. Oehler, S. Grillo, S. DeArmond, S.Prusiner, K. Giles.//

Proc. Natl. Acad. Sci. U.S.A, 2012. – Vol. 109. – P. 11025–11030.

186.Takata K. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors./ K. Takata, Y. Kitamura, M. Saeki, M. Terada, S. Kagitani, R. Kitamura, Y. Fujikawa, A. Maelicke, H. Tomimoto, T. Taniguchi, S. Shimohama.// J Biol Chem., 2010. – Vol. 285(51). – P. 40180-40191.

187.Tanzi R.E. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective./ R.E. Tanzi, L. Bertram.// Cell, 2005. – Vol. 120. – P. 545–555.

188.Terry R.D. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment./ R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, R. Katzman.// Ann Neurol., 1991. – Vol. 30. – P. 572–580.

t.me/medicina_free

113

189.Thinakaran G. Amyloid precursor protein trafficking, processing, and function./ G. Thinakaran, E.H. Koo.// J Biol Chem., 2008. – Vol. 31. – P. 29615–29619.

190.Thomas S.J. Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias./ S.J. Thomas, G.T. Grossberg.//

Clin Interv Aging, 2009. – Vol. 4. – P. 367–377.

191.Tomiyama T. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo./ T. Tomiyama, S. Matsuyama, H. Iso, T. Umeda, H. Takuma, K. Ohnishi, K. Ishibashi, R. Teraoka, N. Sakama, T. Yamashita, K. Nishitsuji, K. Ito, H. Shimada, M.P. Lambert, W.L. Klein, H. Mori.// The Journal of Neuroscience, 2010. – Vol. 30(14). – P. 4845–4856.

192.Touqeer A. Cholinergic system and post-translational modifications: an insight on the role in Alzheimer's disease./ A. Touqeer, Z. Saadia, M. Aamra, M.F. Syeda.// Current Neuropharmacology, 2017. – Vol. 15(4). – P. 480–494.

193.Trinh N.H. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta–analysis./ N.H. Trinh, J. Hoblyn, S. Mohanty, K. Yaffe.// JAMA, 2003. – Vol. 289(2). – P. 210–216.

194.Tsai J. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches./ J. Tsai, J. Grutzendler, K. Duff, W.B. Gan.// Fibrillar Nat Neurosci., 2004. – Vol. 7. – P. 1181–1183.

195.Van der Flier W.M. Epidemiology and risk factors of dementia./ W.M. van der Flier, P. Scheltens.// J Neurol Neurosurg Psychiatry, 2005. – Vol. 76. – P. 2–7.

196.Vassar R. The beta–secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential./ R. Vassar, D.M. Kovacs, R. Yan, P.C. Wong.// J Neurosci., 2009. – Vol. 29(41). – P. 12787–12794.

197.Viayna E. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease–modifying anti–Alzheimer agents./ E. Viayna, I. Sola, M. Bartolini, A. De Simone, C. Tapia–Rojas, F.G. Serrano, R. Sabate, J. Juarez–

t.me/medicina_free

114

Jimenez, B. Perez, F.J. Luque, V. Andrisano, M.V. Clos, N.C. Inestrosa, D.J.

Muñoz–Torrero.// Med Chem., 2014. – Vol. 57(6). – P. 2549–2567.

198.Walsh D.M. A beta oligomers – a decade of discovery./ D.M. Walsh, D.J. Selkoe.// J Neurochem., 2007. – Vol. 101. – P. 1172–1184.

199.Wang H.Y. Beta–Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology./ H.Y. Wang, D.H. Lee, M.R. D'Andrea, P.A. Peterson, R.P. Shank, A.B. Reitz.// J Biol Chem., 2000. –

Vol. 275. – P. 5626–5632.

200.Wang Y. A family of RIM-binding proteins regulated by alternative splicing: Implications for the genesis of synaptic active zones./ Y. Wang, X. Liu, T. Biederer, T.C. Sudhof.// Proc Natl Acad Sci USA, 2002. – Vol. 99. – P. 14464–14469.

201.Wilkinson D. Drugs for treatment of Alzheimer’s disease./ D. Wilkinson.// Int. J.

Clin. Pract., 2001. – Vol. 55(2). – P. 129–134.

202. Winblad B. Memantine in moderate to severe Alzheimer’s disease: a meta– analysis of randomised clinical trials./ B. Winblad, R.W. Jones, Y. Wirth, A. Soffler, H.J. Mobius.// Dement Geriatr Cogn Disord., 2007. – Vol. 24. – P. 20–27.

203. Wisniewski T. Biology of Aβ amyloid in Alzheimer’s disease. T. Wisniewski, J.

Ghiso, B. Frangione.// Neurobiol Dis., 1997. – Vol. 4. – P. 313–328.

204.Wolfe M.S. Two transmembrane aspartates in presenilin–1 required for presenilin endoproteolysis and gamma–secretase activity./ M.S. Wolfe, W. Xia, B.L. Ostaszewski, T.S. Diehl, W.T. Kimberly, D.J. Selkoe./ Nature, 1999. – Vol. 398(6727). – P. 513–517.

205.Wyss–Coray T. Inflammation in neurodegenerative disease –– a double–edged sword./ T. Wyss–Coray, L. Mucke.// Neuron, 2002. – Vol. 35. – P. 419–432.

206.Xie H.Q. Targeting acetylcholinesterase to membrane rafts: a function mediated by the proline-rich membrane anchor (PRiMA) in neurons./ H.Q. Xie, D. Liang, K.W. Leung, V.P. Chen, K.Y. Zhu, W.K. Chan, R.C. Choi, J. Massoulié, K.W.

Tsim.// J Biol Chem., 2010. – Vol. 285(15). – P. 11537-11546.

t.me/medicina_free

115

207.Xu Y. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease./ Y. Xu, J. Yan, P. Zhou, J. Li, H. Gao, Y. Xia, Q. Wang.// Prog Neurobiol., 2012. – Vol. 97(1). – P. 1–13.

208.Yamamoto A. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease./ A. Yamamoto, R.W. Shin, K. Hasegawa, H. Naiki, H. Sato, F. Yoshimasu, T. Kitamoto.// J Neurochem., 2002. –

Vol. 82. – P. 1137–1147.

209.Yan S.D. RAGE and amyloid–beta peptide neurotoxicity in Alzheimer's disease./ S.D. Yan, X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, A.M. Schmidt.// Nature, 1996. – Vol. 382. – P. 685–691.

210.Yuki D. DHA–PC and PSD–95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease./ D. Yuki, Y. Sugiura, N. Zaima,

H.Akatsu, S. Takei, I. Yao, M. Maesako, A. Kinoshita, T. Yamamoto, R. Kon, K. Sugiyama, M. Setou.// Sci Rep.vc, 2014. – Vol. 4.

211.Zheng W.H. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures./ W.H. Zheng, S. Bastianetto, F. Mennicken, W. Ma, S. Kar.// Neuroscience, 2002. – Vol. 115(1). – P. 201–211.

212.Zhu H. Impairments of spatial memory in an Alzheimer's disease model via degeneration of hippocampal cholinergic synapses./ H. Zhu, H. Yan, N. Tang, X. Li,

P.Pang, H. Li, W. Chen, Y. Guo, S. Shu, Y. Cai, L. Pei, D. Liu, M. Luo, H. Man, Q. Tian, Y. Mu, L. Zhu, Y. Lu.// Nat Commun., 2017. – Vol. 8(1) :1676.

213.Zueva I. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease./ I. Zueva, J. Dias, S. Lushchekina, V. Semenov, M. Mukhamedyarov, T. Pashirova, V. Babaev, F. Nachon, N. Petrova, L. Nurullin, L. Zakharova, V. Ilyin, P. Masson, K. Petrov.// Neuropharmacology, 2019. – Vol. 155. – P. 131–141.

214.Кадыков А.С. Болезнь Альцгеймера: механизмы развития и лечение./ А.С. Кадыков, А.В. Кадыков.// Фарматека, 2009. – № 7. – С. 55–57.

t.me/medicina_free

116

215.Миронов А.Н. Руководство по проведению клинических исследований лекарственных средств. Часть первая. / А.Н. Миронов, В.Г. Кукес и др.// Гриф и К, 2012. –С. 244.

216.Сидоров К.К. О классификации токсичности ядов при парентеральных способах введения./ К.К. Сидоров.// Токсикол. Новых пром. хим. веществ,

1973. – №13. – С. 47–51.

t.me/medicina_free